Idera Pharma (IDRA) Announces TLR Patent Issuance
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced the issuance of patents covering its novel Toll-like Receptor (TLR) - targeted compounds. The Company's TLR-targeted compounds are based on synthetic DNA and RNA, which it refers to as immune modulatory oligonucleotides, or IMO. Idera's intellectual property portfolio contains over 500 patents and patent applications worldwide, which includes claims for TLR-targeted compounds, second-generation antisense chemistry, and oral delivery of certain oligonucleotides.
"The claims of these issued patents cover Idera's IMO compositions, the use of IMOs in treating and preventing diseases, and the combination of IMOs with certain monoclonal antibodies for the treatment of cancer," commented Steve Ritter, Ph.D., J.D., Vice President of Intellectual Property and Contracts. "These patents expand the patent protection for TLR-targeted compounds in our pipeline."
Some of Idera's recently issued patents include:
- US 7,595,305, entitled "Modulation Of Immunostimulatory Properties Of Oligonucleotide-Based Compounds By Utilizing Modified Immunostimulatory Dinucleotides"
- US 7,569,554, entitled "Synergistic Treatment of Cancer Using Immunomers in Conjunction with Chemotherapeutic Agents"
- US 7,566,702, entitled "Immunostimulatory Oligonucletide Multimers"
Create E-mail AlertRelated Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
